The new drug, called tisotumab vedotin (or TV for short), releases a toxic substance to kill cancer cells from within. The results have been so positive the drug has now moved forward to phase II trials in cervical cancer and will be tested in a range of additional solid tumour cancers.
medicalxpress.com/news/2019...
Bob
They said it worked on a significant minority of cancer patients and they named a number of cancers. But they said “but not on prostate cancer”. It was not clear if the reason was prostate cancer did not respond or because there were no PC patients that were in the trial. Any idea which one ?
Schwah
"Patients (aged ≥18 years) had relapsed, advanced, or metastatic cancer of the ovary, cervix, endometrium, bladder, prostate, oesophagus, squamous cell carcinoma of the head and neck or non-small-cell lung cancer"
"Between Dec 9, 2013, and May 18, 2015, 27 eligible patients were enrolled to the dose-escalation phase."
"Between Oct 8, 2015, and April 26, 2018, 147 eligible patients were enrolled to the dose-expansion phase."
"Across tumour types, the confirmed proportion of patients who achieved an objective response was 15·6% (95% CI 10·2–22·5; 23 of 147 patients)."
-Patrick
Rife Low Frequency Cancer Treatment
New drug could revolutionise prostate cancer treatment 
Standard of Care for prostate cancer from one country to another 
